FDA lift clinical hold on Adolors Entereg (alvimopan) program for chronic opioid bowel dysfunction (OBD). « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
July 2008

M T W T F S S

« Jun Aug »

1 2 3 4 5 6

7 8 9 10 11 12 13

14 15 16 17 18 19 20

21 22 23 24 25 26 27

28 29 30 31

FDA lift clinical hold on Adolors Entereg (alvimopan) program for chronic opioid bowel dysfunction (OBD).

Posted on July 7, 2008 by crimsoncanary

FDA lift clinical hold on Adolors Entereg (alvimopan) program for chronic opioid bowel dysfunction (OBD).

Filed under: Uncategorized | Tagged: Adolor, alvimopan, antagonist, Entereg, Opioid, Opioid mu

« Merck publish series of Quinazolinone Histamine H3 Receptor Inverse Agonists Sciele complete Phase III trial of Glycopyrrolate for Moderate-to-Severe Drooling »

Leave a Reply